The remarkable response to ponatinib therapy in a child with blastic phase of chronic myeloid leukemia.

CONCLUSION: Ponatinib therapy is effective and promising as a bridge to hematopoietic stem cell transplantation in children. Although more studies are necessary to determine indications, dose, efficacy, and safety data.
PMID: 32558423 [PubMed - in process]

Source: The Turkish Journal of Pediatrics - June 20, 2020 Category: Pediatrics Authors: Aksu T, Ünal Ş, Gümrük F Tags: Turk J Pediatr Source Type: research